Shares of Align Technology, Inc. (NASDAQ:ALGN) have earned a consensus rating of “Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Eleven analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have covered the stock in the last year is $214.45.

ALGN has been the subject of a number of research analyst reports. Credit Suisse Group reiterated an “outperform” rating and issued a $170.00 price target (up from $140.00) on shares of Align Technology in a report on Thursday, July 13th. Morgan Stanley reiterated an “overweight” rating and issued a $182.00 price target (up from $175.00) on shares of Align Technology in a report on Monday, July 17th. Bank of America Corporation upgraded Align Technology from a “neutral” rating to a “buy” rating and boosted their price target for the company from $175.00 to $193.00 in a report on Friday, July 28th. Piper Jaffray Companies reiterated a “buy” rating and issued a $176.00 price target on shares of Align Technology in a report on Friday, July 28th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $199.00 price target (up from $194.00) on shares of Align Technology in a report on Friday, July 28th.

In related news, Director Greg J. Santora sold 7,700 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $238.95, for a total transaction of $1,839,915.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Oppenheimer & Co. Inc. acquired a new position in Align Technology during the 2nd quarter worth $1,768,000. AQR Capital Management LLC boosted its position in Align Technology by 36.7% during the 1st quarter. AQR Capital Management LLC now owns 94,715 shares of the medical equipment provider’s stock worth $10,865,000 after acquiring an additional 25,422 shares during the period. American Century Companies Inc. boosted its position in Align Technology by 2,236.0% during the 2nd quarter. American Century Companies Inc. now owns 221,009 shares of the medical equipment provider’s stock worth $33,178,000 after acquiring an additional 211,548 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in Align Technology by 17.8% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 90,969 shares of the medical equipment provider’s stock worth $13,657,000 after acquiring an additional 13,753 shares during the period. Finally, Chevy Chase Trust Holdings Inc. acquired a new position in Align Technology during the 2nd quarter worth $9,854,000. Hedge funds and other institutional investors own 80.96% of the company’s stock.

Shares of Align Technology (ALGN) opened at $241.35 on Friday. Align Technology has a twelve month low of $85.56 and a twelve month high of $244.60. The firm has a market capitalization of $19,350.96, a P/E ratio of 71.41, a PEG ratio of 2.35 and a beta of 1.42.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.19. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The business had revenue of $385.30 million during the quarter, compared to the consensus estimate of $359.80 million. During the same period in the previous year, the business earned $0.63 EPS. The business’s quarterly revenue was up 38.3% on a year-over-year basis. sell-side analysts expect that Align Technology will post 3.56 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Align Technology, Inc. (ALGN) Receives Average Rating of “Buy” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/05/align-technology-inc-algn-receives-average-rating-of-buy-from-analysts.html.

Align Technology Company Profile

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.